About this trial
This study is evaluating the Sparrow Link, a wearable device that delivers gentle electrical signals to nerves in the outer ear (a technique known as transcutaneous auricular neurostimulation, or tAN). The goal is to assess whether the device is feasible to use, acceptable to patients, and may help reduce opioid withdrawal symptoms in hospitalized adults being treated for opioid use disorder (OUD). Participants will be randomly assigned to receive either the active device or a sham (inactive) version. Neither participants nor their clinical teams will know which version is used. All participants will continue receiving standard hospital care for opioid withdrawal. Researchers will collect information on how long participants use the device, whether they stop using it early, and changes in withdrawal severity. The study will also examine pain, craving, mood, anxiety, heart rate variability, and opioid use during hospitalization.
Eligibility criteria
Qualifiers
Despite Maximal medical therapy with methadone, buprenorphine, full agonist opioids, or non-opioid medications,
During tapering or detox from full agonist opioids.
Have chosen to decline methadone or buprenorphine but still require support for withdrawal symptoms and/or pain management.
Be 18 years old or older.
Disqualifiers
History of or active seizure disorder.
Presence of a cardiac device (e.g., pacemaker, defibrillator).
Presence of a neurostimulator (e.g., deep brain stimulator, spinal cord stimulator).
Pregnant or lactating individuals.
Trial design
Treatments tested in this trial
- Sparrow Link (Active tAN)
- Sparrow Link (Sham tAN)
Treatment groups
Sponsors and collaborators
Payel Roy
Lead sponsor
University of Pittsburgh
Sponsor institution
UPMC Ladies Hospital Aid Society
Collaborator